

PRESS RELEASE



Paris, France – July 16, 2012

Alzheimer's disease: patient enrollment completed ahead of plan in Exonhit's studies on AclarusDx®

- France: 600 patients enrolled in six months as part of the DIALOG study
- U.S.: 160 patients enrolled in the pilot clinical study

Exonhit (NYSE Alternext, ALEHT) announced that patient enrollment was completed ahead of plan in its studies in France and the United States for the assessment of the performance of AclarusDx®, its blood test that detects Alzheimer's disease specific biomarkers.

Exonhit started in December 2011 in France a real life observational study called DIALOG (Diagnosis ALzheimer cOGnitive), an essential step in demonstrating the clinical utility of AclarusDx®. This study aims at evaluating the performance of AclarusDx® in patients consulting for the first time with a memory center and complaining of cognitive disorders and/or memory impairment. It will also enable French specialized memory centers (Centres Mémoire de Ressources et de Recherche, CMRR, or Consultations Mémoire, CM) to get acquainted with the test and assess its position within the current Alzheimer's disease diagnostic work-up

85 physicians working in 18 CMRR and 13 CM actively participated in this study. The recruitment of 600 patients, which was to be completed toward the end of July 2012, ended faster than anticipated, one month ahead of schedule. Follow-up of recruited patients will last one year, and the results of the study should be available during the fourth quarter of 2013.

In the United States, Exonhit also started in November 2011, in collaboration with Professor Jeff Cummings, a pilot clinical study to evaluate the performance of AclarusDx® in U.S. patients with memory impairment who were newly referred to a Reference Memory Center for an Alzheimer's disease diagnostic assessment. The goal of this study is to prepare Exonhit's entry strategy in the United States.

The recruitment of 160 patients with 4 investigators working in three sites of the Cleveland Clinic (Las Vegas, Lakewood and Cleveland) was completed successfully, according to plan.

"The speed with which patients were recruited as part of these two studies is remarkable. I want to highlight the work done by all Memory Centers in France and the United States, which, thanks to their efficiency, enabled us to achieve these ambitious goals in 6 to 7 months. I would like to thank all investigators and their team, who allowed us to successfully implement our development plan" said Dr **Loïc Maurel, President of Exonhit's Management Board.**

About Exonhit

Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer's disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations.

Exonhit is headquartered in Paris, France and has a U.S. subsidiary in Gaithersburg, Maryland. The Company is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts for Media & Investors

EXONHIT

Hervé Duchesne de Lamotte
CFO
+33 1 53 94 52 49
herve.delamotte@exonhit.com

ACTIFIN

Financial Communication
+ 33 1 56 88 11 11

Investors relations,

Alexandre Commerot, acommerot@actifin.fr

Press relations,

Jennifer Jullia, jjullia@actifin.fr